Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 Aug;44(2):208–218. doi: 10.1038/bjc.1981.172

Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.

M P Law, D G Hirst, J M Brown
PMCID: PMC2010739  PMID: 7272187

Abstract

The effect of misonidazole (MISO) on the cytotoxicity of cyclophosphamide (CY) was investigated in the mouse. The response of the RIF-1 tumour was measured by growth delay and by cell survival in a cloning assay. MISO enhanced the cytotoxicity of CY. For single treatment, enhancement was maximal when MISO was given 30 min to 2 h before CY. The enhancement ratio (i.e. the dose of CY alone divided by the dose of CY with MISO required to cause the same response) increased with increasing dose of MISO up to 250 mg/kg, but decreased with increasing dose of CY above 50 mg/kg. For 5 daily treatments, enhancement increased with CY dose up to approximately 25 mg/kg/injection. Survival of marrow stem cells was measured using the spleen-colony assay. MISO did not enhance significantly the cytotoxicity of CY at doses under 100 mg/kg. Enhancement was seen at higher doses, but the effect was less than in tumours. CY reduced the number of circulating white blood cells. Neutrophils were most severely depleted. The WBC count was slightly lower when CY was given in combination with MISO than after CY alone, but the effect could be accounted for by direct MISO cytotoxicity. These experiences suggest that a therapeutic gain may be achieved if MISO is combined with doses of CY in the clinical range. From experiments performed to investigated the possible mechanisms involved, we conclude that for the RIF-1 tumour the major effect of MISO is to inhibit the repair from CY-induced potentially lethal damage.

Full text

PDF
208

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacopoulos N. G., Redmond D. E., Baulu J., Roth R. H. Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (vervet monkey). J Pharmacol Exp Ther. 1980 Jan;212(1):1–5. [PubMed] [Google Scholar]
  2. Bedford J. S., Mitchell J. B. The effect of hypoxia on the growth and radiation response of mammalian cells in culture. Br J Radiol. 1974 Oct;47(562):687–696. doi: 10.1259/0007-1285-47-562-687. [DOI] [PubMed] [Google Scholar]
  3. Begg A. C., Fu K. K., Kane L. J., Phillips T. L. Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival. Cancer Res. 1980 Jan;40(1):145–154. [PubMed] [Google Scholar]
  4. Brown J. M. Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo. Radiat Res. 1977 Dec;72(3):469–486. [PubMed] [Google Scholar]
  5. Brown J. M., Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res. 1980 Apr;82(1):171–190. [PubMed] [Google Scholar]
  6. Clement J. J., Gorman M. S., Wodinsky I., Catane R., Johnson R. K. Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res. 1980 Nov;40(11):4165–4172. [PubMed] [Google Scholar]
  7. Dische S., Saunders M. I., Lee M. E., Adams G. E., Flockhart I. R. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977 May;35(5):567–579. doi: 10.1038/bjc.1977.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gomer C. J., Johnson R. J. Relationship between misonidazole toxicity and core temperature in C3H mice. Radiat Res. 1979 May;78(2):329–333. [PubMed] [Google Scholar]
  9. Hirst D. G., Denekamp J. Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet. 1979 Jan;12(1):31–42. doi: 10.1111/j.1365-2184.1979.tb00111.x. [DOI] [PubMed] [Google Scholar]
  10. Koch C. J., Kruuv J., Frey H. E., Snyder R. A. Plateau phase in growth induced by hypoxia. Int J Radiat Biol Relat Stud Phys Chem Med. 1973 Jan;23(1):67–74. doi: 10.1080/09553007314550061. [DOI] [PubMed] [Google Scholar]
  11. Lefebvre Y., Hesseltine H. C. The peripheral white blood cells and metronidazole. JAMA. 1965 Oct 4;194(1):15–18. [PubMed] [Google Scholar]
  12. Roizin-Towle L., Hall E. J. Studies with bleomycin and misonidazole on aerated and hypoxic cells. Br J Cancer. 1978 Feb;37(2):254–260. doi: 10.1038/bjc.1978.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. TILL J. E., McCULLOCH E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961 Feb;14:213–222. [PubMed] [Google Scholar]
  14. Tannock I. F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer. 1980 Dec;42(6):871–880. doi: 10.1038/bjc.1980.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tannock I. F. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer. 1968 Jun;22(2):258–273. doi: 10.1038/bjc.1968.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Thomlinson R. H., Dische S., Gray A. J., Errington L. M. Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours. Clin Radiol. 1976 Apr;27(2):167–174. doi: 10.1016/s0009-9260(76)80139-0. [DOI] [PubMed] [Google Scholar]
  17. Turner A. R., Allalunis M. J., Urtasun R. C., Pedersen J. E., Meeker B. E. Cytotoxic and radiosensitizing effects of misonidazole on hematopoiesis in normal and tumor-bearing mice. Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1157–1162. doi: 10.1016/0360-3016(80)90168-6. [DOI] [PubMed] [Google Scholar]
  18. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  19. Twentyman P. R., Kallman R. F., Brown J. M. The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1255–1260. doi: 10.1016/0360-3016(79)90649-7. [DOI] [PubMed] [Google Scholar]
  20. Twentyman P. R. Modification of tumour and host response to cyclophosphamide by misonidazole and by WR 2721. Br J Cancer. 1981 Jun;43(6):745–755. doi: 10.1038/bjc.1981.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Twentyman P. R. Sensitivity to cytotoxic agents of the EMT6 tumour in vivo: tumour volume versus in vitro plating. 1. Cyclophosphamide. Br J Cancer. 1977 Feb;35(2):208–217. doi: 10.1038/bjc.1977.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Twentyman P. R. Timing of assays: an important consideration in the determination of clonogenic cell survival both in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1213–1220. doi: 10.1016/0360-3016(79)90641-2. [DOI] [PubMed] [Google Scholar]
  23. Urtasun R. C., Band P., Chapman J. D., Rabin H. R., Wilson A. F., Fryer C. G. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977 Mar;122(3):801–804. doi: 10.1148/122.3.801. [DOI] [PubMed] [Google Scholar]
  24. White R. A., Workman P., Brown J. M. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiat Res. 1980 Dec;84(3):542–561. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES